Bayer (BAYN) Given a €70.00 Price Target by JPMorgan Chase & Co. Analysts

JPMorgan Chase & Co. set a €70.00 ($81.40) price objective on Bayer (FRA:BAYN) in a report released on Tuesday, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.

Several other research firms also recently issued reports on BAYN. Deutsche Bank set a €115.00 ($133.72) target price on Bayer and gave the stock a buy rating in a research report on Friday, March 1st. Barclays set a €85.00 ($98.84) target price on Bayer and gave the stock a buy rating in a research report on Monday, March 4th. Kepler Capital Markets set a €84.00 ($97.67) target price on Bayer and gave the stock a buy rating in a research report on Wednesday, February 27th. Nord/LB set a €72.00 ($83.72) target price on Bayer and gave the stock a neutral rating in a research report on Wednesday, February 27th. Finally, Sanford C. Bernstein set a €86.00 ($100.00) target price on Bayer and gave the stock a buy rating in a research report on Wednesday, February 27th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of €81.67 ($94.97).

Bayer stock opened at €55.28 ($64.28) on Tuesday. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Story: How is diluted EPS different from basic EPS?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.